Skip to content

Preclinical Characterization of [68Ga]Ga/[177Lu]Lu-PSNT-AB: A Dual-Targeted Agent against PSMA and NTSR1 for Prostate Cancer Theranostics.

Oct 2026 · Journal of Medicinal Chemistry · Vol 69 21, pp. 26414-26424 · 0 citations · 37 references
Medicine

Abstract

Prostate-specific membrane antigen (PSMA) is a key biomarker for prostate cancer (PCa), while neurotensin receptor 1 (NTSR1) is positive in PSMA-negative PCa lesions. For comprehensive diagnosis and therapy of PCa, we synthesized dual-targeted PSNT-AB (combining PSMA-targeted EuK, NTSR1-targeted NT-20.3, albumin-binding 4-p-tolylbutyric acid and DOTA moieties) and prepared [68Ga]Ga/[177Lu]Lu-PSNT-AB. [68Ga]Ga-PSNT-AB possessed high affinity for PSMA-positive LNCaP and moderate affinity for NTSR1-positive PC-3 cells. Probes accumulated time-dependently in relevant cells, and [177Lu]Lu-PSNT-AB exerted potent cytotoxicity. Pharmacokinetics revealed prolonged blood half-lives for both probes. PET imaging revealed persistent [68Ga]Ga-PSNT-AB uptake in LNCaP, 22Rv1 and PC-3 tumors (10.29 ± 0.25% ID/g, 6.61 ± 0.30% ID/g, 3.74 ± 0.12% ID/g at 3 h post-injection). SPECT/CT showed sustained [177Lu]Lu-PSNT-AB retention in LNCaP tumors for at least 24 h. These results demonstrated that [68Ga]Ga/[177Lu]Lu-PSNT-AB are promising dual-targeted probes for PCa diagnosis and therapy, offering a potential strategy for comprehensive and effective precision management of PCa.

View source

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.